Literature DB >> 10864184

Human immunodeficiency virus-related tuberculosis and primary drug resistance in Bangkok, Thailand.

J Punnotok1, N Shaffer, T Naiwatanakul, U Pumprueg, P Subhannachart, A Ittiravivongs, C Chuchotthaworn, P Ponglertnapagorn, N Chantharojwong, N L Young, K Limpakarnjanarat, T D Mastro.   

Abstract

SETTING: Central Chest Hospital, a 500-bed referral hospital near Bangkok with a large out-patient department.
OBJECTIVES: To determine human immunodeficiency virus (HIV) seroprevalence among patients with pulmonary tuberculosis (TB), and compare HIV-positive and HIV-negative TB patients.
DESIGN: From July 1995 through June 1996, a cross-sectional study was conducted of newly registered adults (> or =16 years old) with suspected pulmonary TB.
RESULTS: Of 2587 newly registered patients with suspected pulmonary TB, 2019 (78%) received HIV pretest counseling and 1816 (90%) consented to testing. Of these, 364 (20%) were HIV-seropositive. Among 1091 patients with bacteriologically confirmed TB, HIV seroprevalence was 22%. HIV-positive patients were more likely to be young, unemployed, single men and to have a history of injection drug use. HIV-positive patients with first-episode TB were more likely to have Mycobacterium tuberculosis strains resistant to isoniazid (10.9% vs 3.5%; P < 0.001), rifampicin (9.4% vs 2.9%; P < 0.001), and at least isoniazid and rifampicin (multidrug-resistant TB [MDR-TB]; 5.2% vs 0.4%; P < 0.001).
CONCLUSIONS: HIV prevalence is high among TB patients at this Bangkok hospital and is associated with drug resistance, including a 12 times higher risk of MDR-TB. These findings underscore the urgent need to assure adherence to complete, effective TB treatment regimens for all patients, including persons who are potentially difficult to manage such as injection drug users.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864184

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

Review 1.  The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

Review 2.  Tuberculosis and illicit drug use: review and update.

Authors:  Robert G Deiss; Timothy C Rodwell; Richard S Garfein
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

3.  The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada.

Authors:  Paul E Alexander; Prithwish De
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-09       Impact factor: 2.471

4.  Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community.

Authors:  Jason R Andrews; N Sarita Shah; Darren Weissman; Anthony P Moll; Gerald Friedland; Neel R Gandhi
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

Review 5.  Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis.

Authors:  Yonatan Moges Mesfin; Damen Hailemariam; Sibhatu Biadgilign; Sibhatu Biadglign; Kelemu Tilahun Kibret
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

6.  Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL): A cross-sectional observational study protocol using respondent driven sampling.

Authors:  Tara Carney; Jennifer A Rooney; Nandi Niemand; Bronwyn Myers; Danie Theron; Robin Wood; Laura F White; Christina S Meade; Novel N Chegou; Elizabeth Ragan; Gerhard Walzl; Robert Horsburgh; Robin M Warren; Karen R Jacobson
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.752

Review 7.  Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review.

Authors:  Sujit Suchindran; Emily S Brouwer; Annelies Van Rie
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.